8-K: West Pharmaceutical Services Announces CFO Retirement and New Chief Proprietary Segment Officer

West Pharmaceutical Services announces the retirement of its CFO, Bernard Birkett, and the appointment of Shane Campbell as Senior Vice President, Chief Proprietary Segment Officer.

Summary

• West Pharmaceutical Services announced that Bernard Birkett will retire as Senior Vice President & Chief Financial Officer later this year.
• The company has started searching for a successor and is implementing a transition plan.
• Birkett will remain in his current role until a successor is found and then will assume an advisory role until December 31, 2025.
• Shane Campbell has been appointed as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025.
• Campbell joins from Carlisle Companies Inc., where he was Chief Commercial Officer of the Construction Materials business.
• Campbell's employment agreement includes an annual base salary of $600,000 and eligibility for an annual incentive plan bonus with a target of 75% of his base salary in 2025, prorated for his period of employment.
• He will receive a long-term incentive plan award with a grant date fair value of $1,000,000, consisting of performance share units (50%), stock options (25%), and restricted stock units (25%).
• Campbell will also receive a one-time sign-on RSU award with a grant date fair value of $400,000, vesting 25% per year until May 2029, and a sign-on cash bonus of $100,000, subject to a two-year repayment obligation under certain conditions.
• West Pharmaceutical Services generated $2.89 billion in net sales in fiscal year 2024.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The announcement of a CFO's retirement is balanced by the appointment of a new executive, and management expresses confidence in the company's future.

Positives

• Shane Campbell's appointment brings extensive global management experience to West's leadership team.
• The transition plan for Bernard Birkett ensures a smooth handover of CFO responsibilities.
• West's continued growth is supported by strategic leadership appointments.
• The company's financial profile has been strengthened by Birkett's contributions.

Negatives

• The departure of a key executive, the CFO, creates uncertainty until a suitable replacement is found.
• The company faces the challenge of ensuring a seamless transition during the CFO changeover.

Risks

• The timing required to identify a successor to Mr. Birkett is uncertain.
• Failure to effectively manage the CFO transition could negatively impact the company's financial operations.

Future Outlook

The company is focused on identifying a successor for the CFO role and driving its Proprietary Products strategy to ensure long-term growth and success.

Management Comments

• 'Bernard played a critical role along with the Finance and Global Operations teams, in helping West navigate the challenges of the global pandemic, the complexities of destocking, and the emergence of GLP-1s,' said Eric M. Green.
• 'We are thrilled to welcome Shane to our team at West,' said Mr. Green.
• 'His extensive industry experience and strategic vision will be invaluable as we continue to drive our Proprietary Products strategy and ensure West achieves its long-term growth and success,' said Mr. Green.
• 'After great consideration, I have decided to bring my tenure at West to a close in order to pursue new endeavors,' said Mr. Birkett.
• 'With a legacy of over a century of innovation, West is well-positioned to sustain its success well into the future, and I look forward to contributing to the tradition of excellence that pervades the Company,' said Mr. Campbell.

Industry Context

The announcement reflects ongoing executive succession planning, a common practice in publicly traded companies to ensure leadership continuity. The appointment of a Chief Proprietary Segment Officer highlights the company's focus on its proprietary products business, which is a key growth area in the pharmaceutical services industry.

Comparison to Industry Standards

• Executive compensation packages, including base salary, bonus targets, and long-term incentives, are generally in line with industry standards for similar roles at comparable companies in the pharmaceutical and medical device sectors.
• Companies like Catalent, Thermo Fisher Scientific, and Danaher also utilize a mix of cash and equity-based compensation to attract and retain top talent.
• The stock ownership guidelines requiring executives to hold a multiple of their base salary in company stock are a common practice to align executive interests with those of shareholders; for example, Danaher has similar guidelines.
• The change-in-control agreements are also standard practice to provide financial security to executives in the event of a company acquisition.

Management Changes

Stakeholder Impact

• Shareholders may react to the CFO transition and the appointment of a new executive.
• Employees may experience changes in leadership and organizational structure.
• Customers and suppliers are unlikely to be directly impacted by these changes.

Next Steps

• West will continue its search for a new CFO.
• Shane Campbell will assume his role as Senior Vice President, Chief Proprietary Segment Officer, on May 5, 2025.
• The company will host a conference call to discuss its first-quarter 2025 financial results and business expectations.

Key Dates

Keywords

West Pharmaceutical Services, CFO, retirement, Shane Campbell, Chief Proprietary Segment Officer, executive appointment, leadership change, financial results